Rodman & Renshaw Reiterates Market Outperform and PT of $10 on SciClone Pharmaceuticals
Rodman & Renshaw reiterated its Market Outperform rating on SciClone Pharmaceuticals (NASDAQ: SCLN). At the same time, the rating agency left its price target on the company's stock unchanged at $10. On Thursday, SCLN closed the day at $5.07.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.